Vanda Pharmaceuticals (VNDA) EBIT Margin (2010 - 2026)
Vanda Pharmaceuticals (VNDA) posted EBIT Margin of 97.11% for Q1 2026, down 37.69% sequentially from 70.53% in Q4 2025, and down 1512.0% YoY from 6.88% in Q1 2025.
Powered by 
Analysis
Vanda Pharmaceuticals (VNDA) EBIT Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has reported EBIT Margin for 17 years, with the latest figure at 97.11% in Q1 2026.
- Quarterly EBIT Margin fell 1512.0% year-over-year to 97.11% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 73.64% (down 3765.0% YoY) and the FY2025 annual result came in at 69.95%, down 4950.0% from the prior year.
- EBIT Margin fell to 97.11% in Q1 2026 per VNDA's latest filing, from 70.53% in the prior quarter.
- Over five years, EBIT Margin peaked at 10.28% in Q4 2022 and troughed at 97.11% in Q1 2026.
- A 5-year average of 28.57% and a median of 19.33% in 2024 frame the typical range for EBIT Margin.
- The sharpest annual moves came in 2023 and 2025: EBIT Margin jumped 1595 bps in 2023, then tumbled 6253 bps in 2025.
- Over 5 years, EBIT Margin stood at 10.28% in 2022, then plunged by 252 bps to 15.67% in 2023, then dropped by 23 bps to 19.33% in 2024, then sank by 265 bps to 70.53% in 2025, then tumbled by 38 bps to 97.11% in 2026.
- According to Business Quant data, EBIT Margin over the past three periods registered 97.11%, 70.53%, and 55.61% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Vanda Pharmaceuticals | 327.03 Mn | 157.00 Mn | 46.97 Mn | -126.28% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -126.28% |
| Mar 31, 2026 | -97.11% |
| Dec 31, 2025 | -70.53% |
| Sep 30, 2025 | -55.61% |
| Jun 30, 2025 | -73.21% |
| Mar 31, 2025 | -81.99% |
| Dec 31, 2024 | -19.33% |
| Sep 30, 2024 | -23.08% |
| Jun 30, 2024 | -20.10% |
| Mar 31, 2024 | -19.46% |
| Dec 31, 2023 | -15.67% |
| Sep 30, 2023 | -15.45% |
| Jun 30, 2023 | -6.23% |
| Mar 31, 2023 | 3.21% |
| Dec 31, 2022 | 10.28% |
| Sep 30, 2022 | 5.98% |
| Jun 30, 2022 | 5.38% |
| Mar 31, 2022 | -12.74% |
| Dec 31, 2021 | 12.70% |
| Sep 30, 2021 | 15.43% |